Received May 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
An adult 27 years old female patient received a pediatric dose of Engerix-B.; An adult 27 years old female patient received a pediatric dose of Engerix B; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 27-year-old female patient who received HBV (Engerix B) for prophylaxis. Previously administered products included Engerix B (patient took 1st dose on unknown date). On 07-MAY-2025, the patient received the 2nd dose of Engerix B. On 07-MAY-2025, an unknown time after receiving Engerix B, the patient experienced adult use of a child product (Verbatim: An adult 27 years old female patient received a pediatric dose of Engerix-B.) and underdose (Verbatim: An adult 27 years old female patient received a pediatric dose of Engerix B). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 14-MAY-2025 Other HCP reported that they accidentally administered a pediatric dose of Engerix-B to 27 years old adult patient, which led to adult use of a child product and underdose. The vaccine was administered on 7th MAY 2025. It was her second dose of the series. Reporter asked if dose needs to be repeated. Also asked are there any safety concerns.